BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 23792569)

  • 1. Focal adhesion kinase autophosphorylation inhibition decreases colon cancer cell growth and enhances the efficacy of chemotherapy.
    Heffler M; Golubovskaya VM; Dunn KM; Cance W
    Cancer Biol Ther; 2013 Aug; 14(8):761-72. PubMed ID: 23792569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacologic blockade of FAK autophosphorylation decreases human glioblastoma tumor growth and synergizes with temozolomide.
    Golubovskaya VM; Huang G; Ho B; Yemma M; Morrison CD; Lee J; Eliceiri BP; Cance WG
    Mol Cancer Ther; 2013 Feb; 12(2):162-72. PubMed ID: 23243059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancer.
    Hochwald SN; Nyberg C; Zheng M; Zheng D; Wood C; Massoll NA; Magis A; Ostrov D; Cance WG; Golubovskaya VM
    Cell Cycle; 2009 Aug; 8(15):2435-43. PubMed ID: 19571674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FAK and HAS inhibition synergistically decrease colon cancer cell viability and affect expression of critical genes.
    Heffler M; Golubovskaya VM; Conroy J; Liu S; Wang D; Cance WG; Dunn KB
    Anticancer Agents Med Chem; 2013 May; 13(4):584-94. PubMed ID: 22934709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A small molecule focal adhesion kinase (FAK) inhibitor, targeting Y397 site: 1-(2-hydroxyethyl)-3, 5, 7-triaza-1-azoniatricyclo [3.3.1.1(3,7)]decane; bromide effectively inhibits FAK autophosphorylation activity and decreases cancer cell viability, clonogenicity and tumor growth in vivo.
    Golubovskaya VM; Figel S; Ho BT; Johnson CP; Yemma M; Huang G; Zheng M; Nyberg C; Magis A; Ostrov DA; Gelman IH; Cance WG
    Carcinogenesis; 2012 May; 33(5):1004-13. PubMed ID: 22402131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Down-regulation of ALDH1A3, CD44 or MDR1 sensitizes resistant cancer cells to FAK autophosphorylation inhibitor Y15.
    Golubovskaya V; O'Brien S; Ho B; Heffler M; Conroy J; Hu Q; Wang D; Liu S; Cance WG
    J Cancer Res Clin Oncol; 2015 Sep; 141(9):1613-31. PubMed ID: 25656374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of focal adhesion kinase inhibition in non-small cell lung cancer with oncogenically activated MAPK pathways.
    Zhang H; Shao H; Golubovskaya VM; Chen H; Cance W; Adjei AA; Dy GK
    Br J Cancer; 2016 Jul; 115(2):203-11. PubMed ID: 27336608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of focal adhesion kinase decreases tumor growth in human neuroblastoma.
    Beierle EA; Ma X; Stewart J; Nyberg C; Trujillo A; Cance WG; Golubovskaya VM
    Cell Cycle; 2010 Mar; 9(5):1005-15. PubMed ID: 20160475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth.
    Golubovskaya VM; Nyberg C; Zheng M; Kweh F; Magis A; Ostrov D; Cance WG
    J Med Chem; 2008 Dec; 51(23):7405-16. PubMed ID: 18989950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells.
    Zhang J; He DH; Zajac-Kaye M; Hochwald SN
    Cell Cycle; 2014; 13(19):3143-9. PubMed ID: 25486573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Focal adhesion kinase confers pro-migratory and antiapoptotic properties and is a potential therapeutic target in Ewing sarcoma.
    Steinestel K; Trautmann M; Jansen EP; Dirksen U; Rehkämper J; Mikesch JH; Gerke JS; Orth MF; Sannino G; Arteaga MF; Rossig C; Wardelmann E; Grünewald TGP; Hartmann W
    Mol Oncol; 2020 Feb; 14(2):248-260. PubMed ID: 31811703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A small-molecule inhibitor, 5'-O-tritylthymidine, targets FAK and Mdm-2 interaction, and blocks breast and colon tumorigenesis in vivo.
    Golubovskaya VM; Palma NL; Zheng M; Ho B; Magis A; Ostrov D; Cance WG
    Anticancer Agents Med Chem; 2013 May; 13(4):532-45. PubMed ID: 22292771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absence of adhesion triggers differential FAK and SAPKp38 signals in SW620 human colon cancer cells that may inhibit adhesiveness and lead to cell death.
    Walsh MF; Thamilselvan V; Grotelueschen R; Farhana L; Basson M
    Cell Physiol Biochem; 2003; 13(3):135-46. PubMed ID: 12876384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel small molecule inhibitor of FAK and IGF-1R protein interactions decreases growth of human esophageal carcinoma.
    Ucar DA; Cox A; He DH; Ostrov DA; Kurenova E; Hochwald SN
    Anticancer Agents Med Chem; 2011 Sep; 11(7):629-37. PubMed ID: 21707510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FAK inhibition with small molecule inhibitor Y15 decreases viability, clonogenicity, and cell attachment in thyroid cancer cell lines and synergizes with targeted therapeutics.
    O'Brien S; Golubovskaya VM; Conroy J; Liu S; Wang D; Liu B; Cance WG
    Oncotarget; 2014 Sep; 5(17):7945-59. PubMed ID: 25277206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Butyrate regulates the expression of c-Src and focal adhesion kinase and inhibits cell invasion of human colon cancer cells.
    Lee JC; Maa MC; Yu HS; Wang JH; Yen CK; Wang ST; Chen YJ; Liu Y; Jin YT; Leu TH
    Mol Carcinog; 2005 Aug; 43(4):207-14. PubMed ID: 16001424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha-actinin-1 phosphorylation modulates pressure-induced colon cancer cell adhesion through regulation of focal adhesion kinase-Src interaction.
    Craig DH; Haimovich B; Basson MD
    Am J Physiol Cell Physiol; 2007 Dec; 293(6):C1862-74. PubMed ID: 17898132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271.
    Roberts WG; Ung E; Whalen P; Cooper B; Hulford C; Autry C; Richter D; Emerson E; Lin J; Kath J; Coleman K; Yao L; Martinez-Alsina L; Lorenzen M; Berliner M; Luzzio M; Patel N; Schmitt E; LaGreca S; Jani J; Wessel M; Marr E; Griffor M; Vajdos F
    Cancer Res; 2008 Mar; 68(6):1935-44. PubMed ID: 18339875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological profiling of a dual FAK/IGF-1R kinase inhibitor TAE226 in cellular and in vivo tumor models.
    Fukami S; Tomioka D; Murakami Y; Honda T; Hatakeyama S
    BMC Res Notes; 2019 Jun; 12(1):347. PubMed ID: 31215459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer.
    Thanapprapasr D; Previs RA; Hu W; Ivan C; Armaiz-Pena GN; Dorniak PL; Hansen JM; Rupaimoole R; Huang J; Dalton HJ; Ali-Fehmi R; Coleman RL; Sood AK
    Mol Cancer Ther; 2015 Jun; 14(6):1466-1475. PubMed ID: 25833835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.